Anterogen.Co.Ltd (065660) - Total Assets
Based on the latest financial reports, Anterogen.Co.Ltd (065660) holds total assets worth ₩91.44 Billion KRW (≈ $61.97 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Anterogen.Co.Ltd for net asset value and shareholders' equity analysis.
Anterogen.Co.Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Anterogen.Co.Ltd's total assets have evolved over time, based on quarterly financial data.
Anterogen.Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Anterogen.Co.Ltd's total assets of ₩91.44 Billion consist of 38.8% current assets and 61.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 1.3% |
| Accounts Receivable | ₩2.55 Billion | 2.2% |
| Inventory | ₩1.09 Billion | 0.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩284.04 Million | 0.2% |
| Goodwill | ₩5.72 Billion | 4.9% |
Asset Composition Trend (2014–2024)
This chart illustrates how Anterogen.Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Anterogen.Co.Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anterogen.Co.Ltd's current assets represent 38.8% of total assets in 2024, a decrease from 70.6% in 2014.
- Cash Position: Cash and equivalents constituted 1.3% of total assets in 2024, down from 11.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 1.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 4.9% of total assets.
Anterogen.Co.Ltd Competitors by Total Assets
Key competitors of Anterogen.Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Theragen Etex Co.Ltd
KQ:066700
|
Korea | ₩245.25 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩154.14 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩87.88 Billion |
|
Huons Global Co. Ltd
KQ:084110
|
Korea | ₩1.47 Trillion |
Anterogen.Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 41.75 | 47.10 | 4.70 |
| Quick Ratio | 40.94 | 45.91 | 4.51 |
| Cash Ratio | 0.00 | 1.63 | 0.00 |
| Working Capital | ₩48.12 Billion | ₩44.93 Billion | ₩43.22 Billion |
Anterogen.Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Anterogen.Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.04 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -22.3% |
| Total Assets | ₩116.08 Billion |
| Market Capitalization | $194.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values Anterogen.Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Anterogen.Co.Ltd's assets decreased by 22.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Anterogen.Co.Ltd (2014–2024)
The table below shows the annual total assets of Anterogen.Co.Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩116.08 Billion ≈ $78.66 Million |
-22.32% |
| 2023-12-31 | ₩149.43 Billion ≈ $101.27 Million |
+20.38% |
| 2022-12-31 | ₩124.13 Billion ≈ $84.12 Million |
-9.19% |
| 2021-12-31 | ₩136.70 Billion ≈ $92.64 Million |
+45.11% |
| 2020-12-31 | ₩94.20 Billion ≈ $63.84 Million |
+11.36% |
| 2019-12-31 | ₩84.59 Billion ≈ $57.33 Million |
-16.61% |
| 2018-12-31 | ₩101.44 Billion ≈ $68.75 Million |
+74.49% |
| 2017-12-31 | ₩58.14 Billion ≈ $39.40 Million |
+64.10% |
| 2016-12-31 | ₩35.43 Billion ≈ $24.01 Million |
+91.63% |
| 2015-12-31 | ₩18.49 Billion ≈ $12.53 Million |
+27.80% |
| 2014-12-31 | ₩14.47 Billion ≈ $9.80 Million |
-- |
About Anterogen.Co.Ltd
Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regen… Read more